Clinical pharmacokinetics and pharmacodynamics of solifenacin

Clinical Pharmacokinetics

Volumn 48, Issue 5, 2009, Pages 281-302

  Doroshyenko, Oxana ^a   Fuhr, Uwe ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CARBAMAZEPINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DARIFENACIN; DIGOXIN; DRUG METABOLITE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUVOXAMINE; GLYCOPROTEIN P; HYDROXYSOLIFENACIN; KETOCONAZOLE; KETOLIDE; MACROLIDE; MOCLOBEMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; OXYBUTYNIN; PHENYTOIN; PROPIVERINE; PROTEINASE INHIBITOR; RIFAMPICIN; SOLIFENACIN; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

AGE DISTRIBUTION; BLOOD BRAIN BARRIER; BLURRED VISION; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSURIA; ENZYME ACTIVITY; FOOD INTAKE; HEADACHE; HUMAN; IN VITRO STUDY; INTESTINE; KIDNEY CLEARANCE; KIDNEY DISEASE; LIVER DISEASE; LIVER METABOLISM; LONG TERM CARE; MICTURITION; MICTURITION DISORDER; NOCTURIA; NONHUMAN; ORGAN DISTRIBUTION; OVERACTIVE BLADDER; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; QT PROLONGATION; RACE; RECOMMENDED DRUG DOSE; REVIEW; SEX; SINGLE DRUG DOSE; URINARY EXCRETION; URINARY URGENCY; URINE; URINE INCONTINENCE; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PROTEIN BINDING; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY INCONTINENCE;

EID: 67650227695     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200948050-00001     Document Type: Review

References (97)

1. Andersson KE, Chapple C, Weill A. The basis for drug treatment of the overactive bladder. World J Urol 2001 Nov; 19 (5): 294-8
2. Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 2001 Jan; 10 (1): 65-83
3. Masunaga K, Yoshida M, Inadome A, et al. Pharmacological effects of soli-fenacin on human isolated urinary bladder. Pharmacology 2008; 82 (1): 43-52
4. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 Jul; 148 (5): 565-78
5. Hegde SS, Choppin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997 Apr; 120 (8): 1409-18
6. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999; 64 (6-7): 419-28
7. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 14: 531-65
8. Caulfield MP, Birdsall NJ, International Union in Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90
9. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002 Jun; 22 (3): 133-45
10. Fetscher C, Fleichman M, Schmidt M, et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002 Jul; 136 (5): 641-3
11. Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998 Nov; 275 (5 Pt 2): R1654-60
12. Pontari MA, Braverman AS, Ruggieri Sr MR. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004 May; 286 (5): R874-80
13. Stevens L, Chapple CR, Tophill P, et al. A comparison ofmuscarinic receptor- mediated function in the normal and the neurogenic overactive bladder [abstract no. 535]. J Urol 2004; 171: 143
14. Stevens L, Chess-Williams R, Chapple CR. Muscarinic receptor function in the idiopathic overactive bladder [abstract no. 527]. J Urol 2004; 171: 140-1
15. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007 Jan; 30 (1): 54-8
16. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997 Sep; 104 (9): 988-93
17. Appell RA, Abrams P, Dnim HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141-7
18. Epstein BJ, Gums JG, Molina E. Newer agents for the management of overactive bladder. Am Fam Physician 2006 Dec 15; 74 (12): 2061-8
19. Maniscalco M, Singh-Franco D, Wolowich WR, et al. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 2006 Sep; 28 (9): 1247-72
20. Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007 Jul; 20 (3): 307-14
21. Robinson D, Cardozo L. Solifenacin in the management of the overactive bladder syndrome. Int J Clin Pract 2005 Oct; 59 (10): 1229-36
22. Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin (YM905) in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103
23. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004 May 25; 492 (2-3): 243-50
24. Maruyama S, Tsukada H, Nishiyama S, et al. In vivo quantitative auto-radiographic analysis of brain muscarinic receptor occupancy by anti-muscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 2008 Jun; 325 (3): 774-81
25. Okutsu H, Noguchi Y, Ohtake A, et al. Effects of intravenously and orally administered solifenacin succinate (YM905) oncarbachol-induced in- travesical pressure elevation and salivary secretion in mice. Biol Pharm Bull 2007 Dec; 30 (12): 2324-7
26. Meloy TD, Daniels DV, Hegde SS, et al. Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry. Br J Pharmacol 2001 Apr; 132 (7): 1606-14
27. Takeuchi J, Fulton J, Jia ZP, et al. Increased drinking in mutant mice with truncated M5 muscarinic receptor genes. Pharmacol Biochem Behav 2002 May; 72(1-2): 117-23
28. Nakamura T, Matsui M, Uchida K, et al. M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 2004 Jul 15; 558 (Pt 2): 561-75
29. Guay DR. Drug forecast-solifenacin: an investigational anticholinergic for overactive bladder. Consult Pharm 2004 May; 19 (5): 437-44
30. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007 Nov; 100 (5): 987-1006
31. Astellas Pharma US, Inc. and GlaxoSmithKline. Vesicare® (solifenacin succinate tablets): US prescribing information [online]. Available from URL: http://www.astellas.us/docs/vesicare.pdf [Accessed 2009 Mar 24]
32. Uchida T, Krauwinkel WJ, Mulder H, et al. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol 2004 Jul; 58 (1): 4-7
33. Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004 Sep; 44 (9): 1023-33
34. Kuipers ME, Krauwinkel WJ, Mulder H, et al. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D 2004; 5 (2): 73-81
35. Krauwinkel WJ, Smulders RA, Mulder H, et al. Effect of age on the phar-macokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005 May; 43 (5): 227-38
36. Kuipers M, Smulders R, Krauwinkel W, et al. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci 2006 Dec; 102 (4): 405-12
37. Swart PJ, Krauwinkel WJ, Smulders RA, et al. Pharmacokinetic effect of ke-toconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006 Jul; 99 (1): 33-6
38. Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmaco-dynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-95
39. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolter-odine. Clin Pharmacokinet 2001; 40: 227-35
40. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxy-butynin in man. Eur J Clin Pharmacol 1988; 35: 515-20
41. FachInfo Service, Arzneimittel-Informationen furArzte und Apotheker. Vesikur® summary of product characteristics [in German; online]. Available from http://www.fachinfo.de/FachInfo/data/fi/pdf/00/85/008589.pdf [Accessed 2009 May 7]
42. Goepel M, Steinwachs KC. How do medications used to treat urinary incontinence affect the cerebral function of the elderly [in German]? Urologe A 2007 Apr; 46 (4): 387-38
43. Suzuki M, Noguchi Y, Okutsu H, et al. Effect ofantimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 2007 Feb; 557 (28): 154-8
44. Michel MC, Minematsu T, Hashimoto T, et al. In vitro studies on the potential of solifenacin for drug-drug-interactions: plasma protein binding and MDR1 transport [abstract]. Proceedings of the British Pharmacological Society Clinical Pharmacology Section 14-16 December 2004. Br J Clin Pharmacol 2005; 59: 647
45. Michel MC, Yanagihara T, Minematsu T, et al. Disposition and metabolism of solifenacin in humans [abstract]. Proceedings of the British Pharmacological Society Clinical Pharmacology Section 14-16 December 2004. Br J Clin Pharmacol 2005; 59: 647
46. MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WJ, Schentag JJ, Burton ME, editors. Pharmaco- kinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. San Francisco (CA): Applied Therapeutics, Inc., 2005: 82-120
47. Viani A, Rizzo G, Carrai M, et al. Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs. Int J Clin Pharmacol Ther Toxicol 1992 Apr; 30 (4): 128-33
48. Yanagihara T, Kamiyama Y, Iwatsobu T, et al. In vitro metabolism of a new antimuscarinic agent solifenacin succinate in humans [abstract]. Drug Metab Rev 2003; 35 Suppl. 2: 183
49. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995 Jun; 57 (6): 670-7
50. Jeppesen U, Rasmussen BB, Bresen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997 Sep; 62 (3): 279-86
51. Achira M, Suzuki H, Ito K, et al. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4 [abstract]. AAPS PharmSci 1999; 1 (4): E18
52. Gibbs MA, Thummel KE, Shen DD, et al. Inhibition ofcytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999 Feb; 27 (2): 180-7
53. Taekema-Roelvink ME, Swart PJ, Kuipers ME, et al. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin Ther 2005 Sep; 27 (9): 1403-10
54. Smulders RA, Kuipers ME, Krauwinkel WJJ. Multiple doses of the anti- muscarinic agent solifenacin do not affect the pharmacodynamics or phar- macokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Br J Clin Pharmacol 2006; 62 (2): 210-7
55. Smulders RA, Smith NN, Krauwinkel WJ, et al. Pharmacokinetics, safety, and tolerability ofsolifenacin in patients with renal insufficiency. J Pharmacol Sci 2007 Jan; 103 (1): 67-74
56. Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophy 1997; 346: 161-9
57. Yamazaki H, Shaw PM, Guengerich FP, et al. Roles ofcytochromes P450 1A2 and 3A4 in the oxidation ofestradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; l1: 659-65
58. McGrother C, Resnick M, Yalla SV, et al. Epidemiology and etiology of urinary incontinence in the elderly. World J Urol 1998; 16 Suppl. 1: S3-9
59. Brown JS, Posner SF, Stewart AL. Urge incontinence: new health-related quality of life measures. J Am Geriatr Soc 1999 Aug; 47 (8): 980-8
60. DuBeau CE, Kiely DK, Resnick NM. Quality of life impact of urge incontinence in older persons: a new measure and conceptual structure. J Am Geriatr Soc 1999 Aug; 47 (8): 989-94
61. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1989 Oct; 17 (4): 236-63
62. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharma- codynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49-64
63. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection ofthe oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9
64. Food and Drug Administration. Center watch newly approved drug therapies listing [online]. Available from URL: http://www.centerwatch.com/patient/ drugs/dru868.html [Accessed 2008 Jun 20]
65. Smith N, Grimes I, Ridge S, et al. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study. 32nd Annual Meeting, International Continence Society; 2002 Aug 28-30; Heidelberg
66. Chapple CR, Arafio P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004 Jan; 93 (1): 71-7
67. Chapple CR, Rechberger T, Al-Shukri S, et al., YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004 Feb; 93 (3): 303-10
68. Chapple CR, Fianu-Jonsson A, Indig M, et al., STAR Study Group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4mg. Eur Urol 2007 Oct; 52 (4): 1195-203
69. Chapple CR, Martinez-Garcia R, Selvaggi L, et al., for the STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 Sep; 48 (3): 464-70
70. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial ofthe once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 Nov; 172 (5 Pt 1): 1919-24
71. Yamaguchi O, Marui E, Kakizaki H, et al., Japanese Solifenacin Study Group. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with over- active bladder. BJU Int 2007 Sep; 100 (3): 579-87
72. Haab F, Cardozo L, Chapple C, et al., Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 Mar; 47 (3): 376-84
73. Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 2006 Jun; 97 (6): 1256-61
74. Gittelman M. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study [abstract no. TP76]. Int J Gynaecol Obstetr 2003; 83 Suppl. 3: 94
75. Chapple CR, Cardozo L, Steers WD, et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006 Aug; 60 (8): 959-66
76. Gittelman MC, Kaufman J. Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder [abstract 111]. 17th World Congress, International Federation of Gynecology and Obstetrics; 2003 Nov 2-7; Santiago
77. Van Kerrebroeck P, Kreder K, Jonas U, et al., Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urol 2001; 57 (3): 414-21
78. Kreder K, Mayne C, Ionas U. Long-tem safety, tolerability and efficacy of extended-release tolterodine in the treatment ofoveractive bladder. Eur Urol 2002; 41: 588-95
79. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008; 54: 740-64
80. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006 Jan; 22 (1): 41-8
81. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in over-active bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2006 Sep; 17 (5): 512-9
82. Capo' Jr JP, Larameee C, Lucente V, et al. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial. Int J Clin Pract 2008 Jan; 62 (1): 39-46
83. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006 Mar; 4 (1): 14-24
84. Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia reliefin patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2007 Jul; 18 (7): 737-41
85. Wyndaele JJ, De Wachter S. Urgency in overactive bladder: translating experimental data into clinical practice. Drugs Today (Barc) 2008 May; 44 (5): 381-9
86. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54 (3): 543-62
87. Pelman RS, Capo JP, Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of efficacy and safety. Postgrad Med 2008 Jul; 120 (2): 85-91
88. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of over- active bladder. Drugs Aging 2001; 18 (4): 277-304
89. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998 Jan; 81 (1): 42-8
90. Bennett N, O'Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004 Feb; 171 (2 Pt 1): 749-51
91. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. Br J Urol 2005; 95: 580-6
92. Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Invest Drugs 2004; 5: 40-9
93. Basra RK, Wagg A, Chapple C, et al. A review ofadherence to drug therapy in patients with overactive bladder. BJU Int 2008; 102 (7): 774-9
94. Diokno AC, Catipay JR, Steinert BW. Office assessment ofpatient outcome of pharmacologic therapy for urge incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13 (5): 334-8
95. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability oftolterodine. Drugs Aging 2001; 18 (7): 551-60
96. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multi-centre clinical trial to investigate long-termtolerability and efficacy of tros- pium chloride in patients with detrusor instability. World J Urol 2003 May; 20 (6): 392-9
97. Michel MC, Wetterauer U, Vogel M, et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31 (6): 505-14